Parexel has fallen short of its first quarter FY2017 expectations, but is encouraged by new business as it looks to "normalize" cancellation issues.
Envigo has collaborated with InterTek and OCSiAl to develop TUBALL™ single wall carbon nanotubes, which is the first of its kind to complete REACH registration.
The adoption of eTMF solutions is accelerating – with more than 50% of investigative sites expected to have access to a sponsor/CRO eTMF application within three years.
The Chinese Food and Drug Administration (CDFA) has fired back on lack of context in media reporting “80% of China’s clinical trial data are fraudulent.”
With a tax incentive program making clinical trials up to 60% more cost-effective, Australia is a “gateway” to larger studies throughout Asia, says CRO.
Evotec has made an offer to acquire Cyprotex PLC, a preclinical contract research organization (CRO) specializing in ADME-Tox and DMPK.